Open AccessNovel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights
Author(s) -
Mohamed A. Abdelgawad,
Arafa Musa,
Atiah H. Almalki,
Sami I. Alzarea,
Ehab M. Mostafa,
Mostafa M. Hegazy,
Gomaa MostafaHedeab,
Mohammed M. Ghoneim,
Della Grace Thomas Parambi,
Rania B. Bakr,
Nayef S. AlMuaikel,
Abdullah Salah Alanazi,
Metab Alharbi,
Waqas Ahmad,
Syed Nasir Abbas Bukhari,
Mohammad M. AlSanea
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s310820
Subject(s) - pancreatic cancer , egfr inhibitors , epidermal growth factor receptor , cancer research , chemistry , colorectal cancer , cancer , pharmacology , growth inhibition , cytotoxic t cell , cancer cell , metastasis , melanoma , in vitro , biology , medicine , biochemistry , receptor
Epidermal growth factor receptor (EGFR) inhibition is an imperative therapeutic approach targeting various types of cancer including colorectal, lung, breast, and pancreatic cancer types. Moreover, cyclooxygenase-2 (COX-2) is frequently overexpressed in different types of cancers and has a role in the promotion of malignancy, apoptosis inhibition, and metastasis of tumor cells. Combination therapy has been emerged to improve the therapeutic benefit against cancer and curb intrinsic and acquired resistance.